Glucose-Lowering Effects of an Oral Glucokinase (GK) Activator, MK-0941, in Patients with Type 2 Diabetes (T2DM) Inadequately Controlled by Metformin

被引：0
|
作者：
O'Neill, Edward A.
Migoya, Elizabeth
Miller, Jutta
Moreau, Meghan
Maganti, Lata
Larson, Patrick
Gutierrez, Maria
Denoia, Emanuel
Wagner, John A.
Stoch, Aubrey
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2287-PO
引用
收藏
页码：A608 / A608
页数：1
相关论文
共 50 条
  • [1] Additional Glucose-Lowering Effects of the Oral GK Activator, MK-0941, in Patients with T2DM on Basal Insulin
    Migoya, Elizabeth
    Miller, Jutta
    Moreau, Meghan
    Reitman, Christina
    Maganti, Lata
    Larson, Patrick
    Gutierrez, Maria
    Morrow, Linda
    Denoia, Emanuel
    Gottesdiener, Keith
    Wagner, John A.
    [J]. DIABETES, 2011, 60 : A595 - A595
  • [2] MK-0941, a novel glucokinase activator (GKA), lowers HbA1c in type 2 diabetes (T2DM) but lacks glycaemic durability
    Meininger, G. E.
    Shentu, Y.
    Chen, Y.
    Yu, Q.
    Sheng, D.
    Musser, B. J.
    Alba, M.
    Zhang, B. B.
    Migoya, E. M.
    Ehrhart, J.
    Kaufman, K. D.
    Goldstein, B. J.
    [J]. DIABETOLOGIA, 2010, 53 : S107 - S107
  • [3] Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
    Meininger, Gary E.
    Scott, Russell
    Alba, Maria
    Yue Shentu
    Luo, Edmund
    Amin, Himal
    Davies, Michael J.
    Kaufman, Keith D.
    Goldstein, Barry J.
    [J]. DIABETES CARE, 2011, 34 (12) : 2560 - 2566
  • [4] Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs
    Eiki, Jun-ichi
    Nagata, Yasufumi
    Futamura, Mayumi
    Sasaki-Yamamoto, Kaori
    Iino, Tomoharu
    Nishimura, Teruyuki
    Chiba, Masato
    Ohyama, Sumika
    Yoshida-Yoshimioto, Riki
    Fujii, Kenji
    Hosaka, Hideka
    Goto-Shimazaki, Hiroko
    Kadotani, Akito
    Ohe, Tomoyuki
    Lin, Songnian
    Langdon, Ronald B.
    Berger, Joel P.
    [J]. MOLECULAR PHARMACOLOGY, 2011, 80 (06) : 1156 - 1165
  • [5] Improved glycemic control with oral recombinant human insulin in patients with type 2 diabetes (T2DM) inadequately controlled on metformin
    Goldberg, Michael
    Dinh, Steve
    Castelli, Cristina
    Majuru, Shingai
    Arbit, Ehud
    [J]. DIABETES, 2007, 56 : A121 - A122
  • [6] Blood Glucose Lowering Effects of Dextromethorphan in People with Type 2 Diabetes Mellitus (T2DM)
    Stirban, Alin
    Marquard, Jan
    Wnendt, Stephan
    Herebian, Diran
    Schliess, Freimut
    Heise, Tim
    Lammert, Eckhard
    [J]. DIABETES, 2014, 63 : A275 - A275
  • [7] Utilization of Glucose-Lowering Drugs in Patients with T2DM and Established CVD in the US
    Ganz, Michael L.
    Ustyugova, Anastasia V.
    Sawalhi-Leckenby, Nicola
    De Souza, Sabrina
    Gao, Ran
    Homsy, Diana
    Gunnarsson, Erik
    Zhang, Lu
    Desai, Nihar
    [J]. DIABETES, 2020, 69
  • [8] LY2599506, a Novel Glucokinase Activator (GKA), Improves Fasting and Postprandial Glucose in Patients with Type 2 Diabetes Mellitus (T2DM)
    Bue-Valleskey, Juliana M.
    Schneck, Karen B.
    Sinha, Vikram P.
    Wondmagegnehu, Eshetu T.
    Kapitza, Christoph
    Miller, Jeffrey W.
    [J]. DIABETES, 2011, 60 : A272 - A272
  • [9] Efficacy and Safety of Saxagliptin Add-on to Metformin Compared with Acarbose Add-on to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Monotherapy
    Du, Jin
    Liang, Li
    Fang, Hui
    Xu, Fengmei
    Li, Wei
    Shen, Liya
    Mu, Yiming
    [J]. DIABETES, 2016, 65 : A293 - A293
  • [10] Glucose-lowering treatments and COVID-19 mortality in T2DM
    Hadjadj, Samy
    Wargny, Matthieu
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2021, 17 (07) : 387 - 388
12345